Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

NCT05730673 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped No participants enrolled

Conditions

CCR5
Microsatellite Stable
Metastatic
Colorectal Cancer

Interventions

DRUG: 700mg leronlimab weekly dose
DRUG: 80mg Regorafenib at week 1
DRUG: 120mg Regorafenib at week2
DRUG: 160 mg Regorafenib at week 3

Sponsor

CytoDyn, Inc.

Collaborators

[object Object]